Key result
Continuing acetylsalicylic acid during cutaneous surgery did not significantly increase the risk of significant postoperative bleedings compared to discontinuation (RD 0.004; 95% CI -0.003 to 0.019).
Why the study?
The complication risks associated with perioperative discontinuation versus continuation of antithrombotic agents, and bridging vitamin K antagonists with heparin versus continuation during cutaneous surgery, needed clarification.
Does the continuation of antithrombotic agents or bridging with heparin increase the risk of significant postoperative bleedings in patients undergoing cutaneous surgery compared to discontinuation?
Systematic Review
Does the continuation of antithrombotic agents or bridging with heparin increase the risk of significant postoperative bleedings in patients undergoing cutaneous surgery compared to discontinuation?
Effect estimate: RD 0.004 (95% CI -0.003 to 0.019)
There are no clear indications of major bleeding risks when continuing antithrombotic agents during minor skin surgeries, but bridging vitamin K antagonists with heparin may increase bleeding risk.
BACKGROUND AND OBJECTIVES: We aimed to determine the risk of complications during cutaneous surgery for the perioperative discontinuation in comparison to the continuation of antithrombotic agents and the bridging of vitamin K antagonists with heparin in comparison to their continuation. METHODS: We conducted a systematic review, searching three databases for eligible studies. Methods followed the Cochrane Handbook. We used RoB 2 and ROBINS-I to assess risk of bias. The quality of evidence was judged (GRADE). Fixed-effect meta-analyses were performed. RESULTS: Two randomized-controlled trials and 19 prospective cohort studies were included. It is uncertain whether, compared to its discontinuation, continuing acetylsalicylic acid (risk difference (RD) 0.004, 95 % confidence interval (CI) -0.003 to 0.019) perioperatively increases the risk of significant postoperative bleedings (SPB). Compared to its discontinuation, continuing phenprocoumon perioperatively may increase the risk of SPB (RD 0.02, 95 % CI 0.00 to 0.05). Bridging phenprocoumon with heparin perioperatively may increase the risk of SPB when compared to its continuation (RD 0.07, 95 % CI 0.01 to 0.22). No evidence was found regarding bleeding risks for direct oral anticoagulants. CONCLUSIONS: No clear indications of major risks of bleedings when continuing antithrombotic agents during minor skin surgeries were identified. However, the quality of evidence was very low.
No takes yet. Share an insight, caveat, or question.
Scherer et al. (2021) conducted a systematic review in Cutaneous surgery. Continuation of antithrombotic agents vs. Discontinuation or bridging was evaluated on Significant postoperative bleedings (SPB) (RD 0.004, 95% CI -0.003 to 0.019). Continuing acetylsalicylic acid during cutaneous surgery did not significantly increase the risk of significant postoperative bleedings compared to discontinuation (RD 0.004; 95% CI -0.003 to 0.019).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: